Linerixibat eases ‘relentless’ PBC itching in Phase 3 trial, meeting goal
Treatment with linerixibat, an oral medication in development by GlaxoSmithKline (GSK), led to significant reductions in pruritus, or itching, among adults with primary…
News
Biomarkers of inflammation could help identify ICP, study finds
Women with intrahepatic cholestasis of pregnancy (ICP), the most common pregnancy-related liver complication, have significantly higher scores of two whole-body inflammation biomarkers than women…
Semaglutide shows liver benefits in Phase 3 MASH trial
Weekly injections of semaglutide, a medication sold in the U.S. under brand names including Ozempic and Wegovy to treat type 2 diabetes and obesity, reduced…
Maralixibat reduces itch in children with biliary atresia: Case series
Off-label treatment with Mirum Pharmaceuticals’ maralixibat led to clinically meaningful reductions in severe itching, or pruritus, in five children with biliary atresia, including…
Phase 3 trials of treatment combo for hepatitis D expected in 2025
On the heels of positive Phase 2 clinical trial data, Vir Biotechnology is planning for the 2025 launch of a Phase 3 program, dubbed…
PBC treatment Livdelzi shows benefits for 2.5 years in Phase 3 trial
After 2.5 years of Livdelzi (seladelpar) treatment, more than 4 in 5 adults with primary biliary cholangitis (PBC) saw meaningful reductions in liver…
Bylvay eases itch over long term in PFIC, Alagille syndrome patients
Nearly 1.5 years of treatment with Bylvay (odevixibat) effectively reduces itching and liver damage markers, and improves growth and sleep in people with…
Fatty liver disease affects 45% of teens, adults in US, Hispanics most
About 45% of teens and adults in the U.S. have some form of fatty liver disease, with Hispanic populations being more affected than other…
Case study highlights challenges to diagnosis of Alagille syndrome
A diagnosis of Alagille syndrome can be challenging, particularly in areas that lack access to genetic testing and specialized imaging, a case report from…
Study uncovers how hepatitis E can lead to kidney damage
Researchers have identified a possible mechanism by which infection with the hepatitis E virus (HEV), a known cause of liver inflammation, can lead to…
